KYMR

Kymera Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↓ 0/10
Kymera Therapeutics sales and earnings growth
KYMR Growth
Low
  • Revenue Y/Y↓ -30.46%
  • EPS Y/Y↓ -15.11%
  • FCF Y/Y↓ -1.68%
Kymera Therapeutics gross and profit margin trends
KYMR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -612.00%
  • ROIC 5Y↓ -28.74%
Kymera Therapeutics net debt vs free cash flow
KYMR Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -881.4

Kymera Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks